Disease Description (Causes and Symptoms)
- Disease name: Primary Biliary Cholangitis (English: Primary Biliary Cholangitis; former name: Primary Biliary Cirrhosis)
- Definition/Pathophysiology: A chronic liver disease in which the small bile ducts within the liver are gradually destroyed through an autoimmune mechanism, leading to cholestasis and progressive liver fibrosis, which may eventually progress to cirrhosis and liver failure. Antimitochondrial antibodies (AMA) are frequently present.
- Main causes: The exact cause is unknown. Multiple factors are believed to act together, including genetic predisposition, environmental triggers (such as infections and toxic substances), and immune abnormalities (autoimmune reactions).
- Main symptoms: Fatigue, severe itching (especially at night), jaundice (as the disease progresses), diarrhea and weight loss due to fat malabsorption, fat-soluble vitamin deficiencies (vitamins A, D, E, and K), osteoporosis, and hypercholesterolemia. As the disease progresses, portal hypertension (such as esophageal varices) and hepatic complications may occur.
Treatment Methods
- First-line drug therapy
- Ursodeoxycholic acid (UDCA): Standard oral administration of 13–15 mg/kg per day (divided into multiple doses). There is evidence that it improves biochemical response and delays disease progression.
- Obeticholic acid (OCA): Used as adjunctive therapy in patients with an insufficient response to UDCA or intolerance to UDCA (caution regarding dosage, indications, and use in liver failure).
- Fibrates (e.g., bezafibrate): Reported to improve ALP in some patients and may be considered as adjunctive treatment.
- Symptomatic treatment
- Itching: The first-line medication is a bile acid sequestrant (e.g., cholestyramine); if unsuccessful, rifampicin, naltrexone, sertraline, or other options may be considered. Pay attention to drug interactions and adverse effects.
- Supplementation with fat-soluble vitamins (A, D, E, and K) and calcium, as well as prevention and treatment of osteoporosis (such as calcitonin and bisphosphonates), should be provided when necessary.
- Complication management
- Portal hypertension/esophageal varices: Screening (endoscopy) and appropriate treatment (endoscopic ligation or medication) should be performed.
- Liver transplantation should be considered in end-stage liver failure or in cases of poor treatment response or life-threatening complications (such as intractable itching or severe osteoporosis).
- Lifestyle management and precautions
- Limit alcohol (cessation is recommended), use caution with hepatotoxic medications, maintain adequate nutritional intake (maintain caloric intake; medium-chain fatty acids may be used if necessary), and manage body weight.
- Vaccinations: Hepatitis A and B vaccinations are recommended for those without immunity; routinely recommended vaccines such as influenza vaccination should also be considered.
- Monitoring
- Blood tests: Regularly check ALP, GGT, bilirubin, AST/ALT, albumin, INR, complete blood count, and other parameters.
- Bone mineral density testing, fat-soluble vitamin and lipid testing, and AMA/immunologic markers should be checked.
- Biochemical treatment response is usually assessed within 6–12 months after starting UDCA, including a reduction in ALP.
Checklist Before an Outpatient Visit (Including Items to Bring and Sample Questions)
- Items to bring to the outpatient visit
- A list of all medications and supplements currently being taken (including dosage and dosing interval)
- Previous blood test and imaging results (liver function tests, ALP, AMA results, ultrasound/MRCP, etc.) or a summary of the results
- A symptom diary (the timing and frequency of fatigue, itching severity, jaundice, digestive problems, weight changes, etc.)
- A history of fractures and osteoporosis-related test results, if available
- Examples of questions to prepare in advance for the outpatient visit
- What are my recent ALP and bilirubin levels, and what are the treatment target levels?
- How long should I expect my current medication (e.g., UDCA) to take effect, and when would I switch to another medication?
- Do I need fat-soluble vitamin or calcium supplementation, and when should I have a bone mineral density test?
Examples of General Questions to Ask the Doctor
- What are the expected benefits and possible side effects of this medication (UDCA/obeticholic acid, etc.)?
- What do my current blood test results (e.g., ALP and bilirubin) mean, and what is my prognosis?
- Are there any foods, medications, or behaviors I should specifically avoid in daily life?
- When might a liver transplant become necessary, and what warning signs should I expect?
Examples of Disease-Specific Questions
- My antimitochondrial antibody (AMA) test is positive/negative. How does this result affect my diagnosis and prognosis?
- After starting UDCA, at what point and ALP level is a patient considered to be “responding to treatment” (e.g., what percentage reduction from baseline or what absolute-value criterion)?
- Because I am at risk for osteoporosis, when should I start DXA (bone mineral density) testing, and how often should it be repeated?
- Is it necessary to test for coexisting autoimmune diseases (e.g., Sjögren syndrome or thyroid disease)?
(When consulting with your healthcare provider, use the questions above as a basis and request a specific plan based on your individual test results and symptoms.)